RTs Three Key Takeaways: GLP-1s for Sleep Apnea Lead Interest: A global survey by Sermo revealed that healthcare providers are most eager to see GLP-1 medications approved for sleep apnea, with 57% of respondents selecting this condition as their top choice
There is a class of drugs that lead to weight loss, glucagon-like peptide 1 (GLP-1) agonists and the total GLP-1 market (includes peptides, orals and injectables), is estimated to be worth ~$37 billion in 2023, with projected growth to $138 billion by 2031
Todays announcement sets a path for our portfolio to potentially transform the lives of hundreds of millions of people and represents an excellent outcome for our shareholders
I started using Stamina-Extra in January this year, my mum had been using your products for a while and suggested it might help my competing dog Zest recover quicker after competition especially in the heat
Phase 1/2 trial reported no serious adverse events at doses up to 60 mcg/kg (Teichman et al., J Clin Endocrinol Metab 2006)
We recommend thinking of your intended use when assessing electrolyte replacements
